ANCA testing, particularly for myeloperoxidase-ANCA (MPO-ANCA), has a sensitivity of approximately 40% in EGPA patients, and is associated with more vasculitic features such as glomerulonephritis, neuropathy, and skin manifestations (39). Here, MPO is linked to glomerulonephritis.